Table 1.
Baseline characteristics of the study population by eGFR (milliliters per minute per 1.73 m2) category at time of qualifying event
| Baseline Variable | eGFR<45, n=1018 | eGFR=45–59, n=2743 | eGFR=60–89, n=9572 | eGFR≥90, n=4682 | Total, n=18,015 |
|---|---|---|---|---|---|
| Age, yr | 73.3 (8.96) | 69.9 (9.22) | 64.5 (9.20) | 58.0 (7.09) | 64.1 (9.76) |
| Men (%) | 602 (59.1) | 1885 (68.7) | 7367 (77.0) | 3776 (80.6) | 13,630 (75.7) |
| White (%) | 851 (83.6) | 2286 (83.3) | 8091 (84.5) | 3883 (82.9) | 15,111 (83.9) |
| BMI, kg/m2 | 28.9 (5.54) | 28.3 (5.09) | 28.2 (5.12) | 28.3 (5.40) | 28.3 (5.22) |
| Current smoker (%) | 159 (15.6) | 591 (21.5) | 2905 (30.4) | 2280 (48.7) | 5935 (33.0) |
| Medical history | |||||
| Hypertension (%) | 856 (84.1) | 2015 (73.5) | 5719 (59.7) | 2483 (53.0) | 11,073 (61.5) |
| Diabetes (%) | 443 (43.5) | 830 (30.3) | 2365 (24.7) | 1264 (27.0) | 4902 (27.2) |
| Prior MI (%) | 311 (30.6) | 727 (26.5) | 1967 (20.6) | 775 (16.6) | 3780 (21.0) |
| Prior PCI (%) | 137 (25.8) | 317 (23.3) | 912 (19.2) | 418 (17.6) | 3537 (19.6) |
| Prior CABG (%) | 203 (19.9) | 365 (13.3) | 864 (9.0) | 243 (5.2) | 1675 (9.3) |
| Prior AF (%) | 125 (12.3) | 242 (8.8) | 452 (4.7) | 123 (2.6) | 942 (5.2) |
| Creatinine, mg/dl | 1.65 (0.36) | 1.26 (0.17) | 1.00 (0.14) | 0.78 (0.12) | 1.02 (0.27) |
| eGFR | 37.6 (5.82) | 53.6 (4.19) | 75.2 (8.44) | 98.7 (7.73) | 75.9 (18.8) |
| CrCl, ml/min | 44.1 (12.1) | 60.9 (15.1) | 85.4 (21.1) | 122.6 (38.1) | 89.0 (34.5) |
| SBP, mmHg | 129.8 (19.4) | 126.5 (18.7) | 125.1 (18.4) | 123.1 (17.8) | 125.0 (18.4) |
| DBP, mmHg | 72.0 (12.1) | 72.1 (11.1) | 73.2 (11.2) | 73.4 (11.1) | 73.0 (11.2) |
| LDL-C, mg/dl | 88.4 (21.1) | 90.8 (20.3) | 94.1 (19.9) | 96.1 (19.4) | 93.8 (20.0) |
| HDL-C, mg/dl | 41.4 (13.5) | 42.0 (13.5) | 42.5 (13.1) | 41.7 (13.0) | 42.1 (13.1) |
| TGs, mg/dl | 136.6 (74.1) | 135.0 (72.9) | 135.3 (74.5) | 143.6 (79.5) | 137.5 (75.7) |
| Medications before qualifying event (%) | |||||
| β-Blockers | 912 (89.6) | 2522 (92.0) | 8783 (91.8) | 4341 (92.7) | 16,558 (91.9) |
| ACEi or ARB | 681 (67.0) | 1934 (70.6) | 6755 (70.6) | 3288 (70.3) | 12,658 (70.3) |
| Statins | 454 (44.6) | 1208 (44.1) | 3253 (34.0) | 1289 (27.6) | 6204 (34.5) |
| Follow-up, mo | |||||
| Overall | |||||
| Median | 55.6 | 66.7 | 72.4 | 73.7 | 71.4 |
| Interquartile range | 30.5–78.9 | 49.0–85.0 | 52.0–86.0 | 53.2–85.9 | 51.4–85.7 |
| On Treatment | |||||
| Median | 32.7 | 50.2 | 54.7 | 55.2 | 53.1 |
| Interquartile range | 6.0–61.0 | 13.0–76.8 | 19.4–80.6 | 21.1–80.3 | 17.1–79.2 |
Data are presented as n (%) or mean (SD) unless otherwise defined. BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; AF, atrial fibrillation; SBP, systolic BP; DBP, diastolic BP; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglyceride; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.